{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:14:13Z","timestamp":1771629253275,"version":"3.50.1"},"reference-count":33,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RAs may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across a patient's risk with a particular focus on HF. After a careful review of the literature, we challenge the current views about the use of GLP-1 RAs and suggest performing active HF screening (with directed clinical history, physical examination, an echocardiogram, and natriuretic peptides) before initiating a GLP-1 RA. After HF screening, we suggest GLP-1 RA treatment decisions as follows: (1) in people with T2D without HF, GLP-1 RAs should be used for reducing the risk of myocardial infarction and stroke, with a possible effect to reduce the risk of HF hospitalizations; (2) in patients with HF and preserved ejection fraction, GLP-1 RAs do not reduce HF hospitalizations but may reduce atherosclerotic events, and their use may be considered in an individualized manner; and (3) in patients with HF and reduced ejection fraction, the use of GLP-1 RAs warrants caution due to potential risk of worsening HF events and arrhythmias, pending risk\u2013benefit data from further studies.<\/jats:p>","DOI":"10.1210\/clinem\/dgad398","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T11:37:32Z","timestamp":1688643452000},"page":"4-9","source":"Crossref","is-referenced-by-count":46,"title":["Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"UnIC@RISE, Department of Surgery and Physiology, Cardiovascular Research and Development Center, University of Porto , Porto , Portugal"},{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques Plurith\u00e9matique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy , France"},{"name":"Heart Failure Clinic, Centro Hospitalar de Vila Nova de Gaia\/Espinho , Vila Nova de Gaia , Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-8330","authenticated-orcid":false,"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[{"name":"Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre, Division of Cardiology McGill University Health Centre McGill University, DREAM-CV Laboratory McGill University Health Centre McGill University , Montreal, QC , Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX , USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Heart and Vascular Institute, Baylor University Medical Center , Dallas, TX , USA"},{"name":"Imperial College , London , UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques Plurith\u00e9matique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy , France"}]},{"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[{"name":"UnIC@RISE, Department of Surgery and Physiology, Cardiovascular Research and Development Center, University of Porto , Porto , Portugal"},{"name":"Department of Internal Medicine, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o , Porto , Portugal"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[{"name":"UnIC@RISE, Department of Surgery and Physiology, Cardiovascular Research and Development Center, University of Porto , Porto , Portugal"}]},{"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[{"name":"UnIC@RISE, Department of Surgery and Physiology, Cardiovascular Research and Development Center, University of Porto , Porto , Portugal"},{"name":"Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o , Porto , Portugal"}]}],"member":"80","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"issue":"Suppl 1","key":"2023122122175226400_dgad398-B1","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"2023122122175226400_dgad398-B2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2023122122175226400_dgad398-B3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/dom.14707","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials","volume":"24","author":"Leite","year":"2022","journal-title":"Diabetes Obesity Metab"},{"issue":"1","key":"2023122122175226400_dgad398-B4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2023122122175226400_dgad398-B5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"2023122122175226400_dgad398-B6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2023122122175226400_dgad398-B7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"issue":"23","key":"2023122122175226400_dgad398-B8","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2023122122175226400_dgad398-B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2023122122175226400_dgad398-B10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2023122122175226400_dgad398-B11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10157","key":"2023122122175226400_dgad398-B12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"2023122122175226400_dgad398-B13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"2023122122175226400_dgad398-B14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2023122122175226400_dgad398-B15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"2023122122175226400_dgad398-B16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2023122122175226400_dgad398-B17","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"2023122122175226400_dgad398-B18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/ejhf.2660","article-title":"Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from harmony outcomes","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"2023122122175226400_dgad398-B19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2023122122175226400_dgad398-B20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2023122122175226400_dgad398-B21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"2023122122175226400_dgad398-B22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2023122122175226400_dgad398-B23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 diabetes\u2014microvascular and cardiovascular outcomes","volume":"387","author":"Nathan","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2023122122175226400_dgad398-B24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2016.01.008","article-title":"Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction","volume":"4","author":"Lepore","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"7","key":"2023122122175226400_dgad398-B25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"issue":"36","key":"2023122122175226400_dgad398-B26","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"Esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"2023122122175226400_dgad398-B27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"Acc\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2023122122175226400_dgad398-B28","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"4","key":"2023122122175226400_dgad398-B29","doi-asserted-by":"crossref","first-page":"bvz042","DOI":"10.1210\/jendso\/bvz042","article-title":"Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity","volume":"4","author":"Iacobellis","year":"2020","journal-title":"J Endocr Soc"},{"issue":"11","key":"2023122122175226400_dgad398-B30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/eurheartj\/ehu401","article-title":"Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program","volume":"36","author":"Vazir","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"2023122122175226400_dgad398-B31","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"11","key":"2023122122175226400_dgad398-B32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/hh2301.100003","article-title":"Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A","volume":"89","author":"Antos","year":"2001","journal-title":"Circ Res"},{"issue":"4","key":"2023122122175226400_dgad398-B33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ejhf.1047","article-title":"Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad398\/50959440\/dgad398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/1\/4\/54731305\/dgad398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/1\/4\/54731305\/dgad398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T22:18:30Z","timestamp":1703197110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/1\/4\/7220075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,6]]},"published-print":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad398","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,7,6]]}}}